Morinaga Milk Industry Co., Ltd. announced that its probiotic strain Bifidobacterium breve B-3 has been approved by South Korea for its efficacy in reducing body fat. This Individual Recognized Registration (No. 2023-2) validates the strain’s safety, functionality, and regulatory compliance.

Clinical Benefits of B. breve B-3

B. breve B-3, developed by Morinaga Milk, is known for its positive impact on metabolic syndrome, weight management, and overall well-being. The strain can be used as a functional ingredient for body fat reduction at a dosage of 5 billion CFU/day, backed by clinical evidence supporting its effectiveness.

Regulatory Compliance and Market Impact

South Korea’s regulatory environment for functional ingredients requires rigorous standards. Morinaga Milk’s B. breve B-3 meets these requirements, showcasing the company’s commitment to high-quality, science-backed health solutions. This approval is expected to enhance Morinaga Milk’s presence in South Korea’s growing probiotic market.

Recent Clinical Study Reinforces Strain’s Efficacy

A recent randomized clinical trial in South Korea confirmed the effectiveness of B. breve B-3 in reducing body fat and improving metabolic health. The study, published in Nutrients, demonstrated significant reductions in body weight, fat, waist, and hip circumference among participants taking the probiotic strain.

  Morinaga Milk Industry, probiotics, South Korea, weight management